1453211-53-4

Upstream product

• 171290-52-1 1-Ethynyl-3,5-dimethoxy-benzene 
• 1445-39-2 2-amino-5-iodopyrimidine 
• 1453211-49-8 3-ethynyl-2,4-difluoro-1,5-dimethoxybenzene 
• 1560796-28-2 [(2,6-difluoro-3,5-dimethoxyphenyl)ethynyl](trimethyl)silane 
• 1560796-27-1 2,4-difluoro-3-iodo-1,5-dimethoxybenzene 
• 651734-54-2 2,6-difluoro-3,5-dimethoxybenzeneamine 

Downstream Products

• 1453207-62-9 5-[2-(2,6-difluoro-3,5-dimethoxyphenyl)ethyl]-N-[1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl]pyrimidin-2-amine 
• 1453211-55-6 2-chloro-5-[2-(2,6-difluoro-3,5-dimethoxyphenyl)ethyl]pyrimidine 
• 1453211-54-5 5-[(2,6-difluoro-3,5-dimethoxyphenyl)ethyl]pyrimidin-2-amine 
• 1453208-94-0 5-[2-(2,6-difluoro-3,5-dimethoxyphenyl)ethyl]-N-(3-methoxy-4-{4-[(1-methylpiperidin-4-yl)amino]piperidin-1-yl}phenyl)pyrimidin-2-amine 
• 1453212-51-5 5-[2-(2,6-difluoro-3,5-dimethoxyphenyl)ethyl]-N-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-3-methoxyphenyl]pyrimidin-2-amine 

Relevant academic research and scientific papers

COMPOUNDS FOR INHIBITING FGFR4

Provided herein are compounds which inhibit FGFR4, compositions thereof, methods of their preparation, and methods for treating disorders mediated by FGFR4 such as cancer.

NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.